0001171843-23-004942.txt : 20230803 0001171843-23-004942.hdr.sgml : 20230803 20230803070408 ACCESSION NUMBER: 0001171843-23-004942 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230803 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230803 DATE AS OF CHANGE: 20230803 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOCRYST PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000882796 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 621413174 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23186 FILM NUMBER: 231138007 BUSINESS ADDRESS: STREET 1: 4505 EMPEROR BOULEVARD STREET 2: SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 BUSINESS PHONE: 919-859-1302 MAIL ADDRESS: STREET 1: 4505 EMPEROR BOULEVARD STREET 2: SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 8-K 1 f8k_080323.htm FORM 8-K Form 8-K
0000882796 False 0000882796 2023-08-03 2023-08-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  August 3, 2023

_______________________________

BioCryst Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware000-2318662-1413174
(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

4505 Emperor Blvd., Suite 200

Durham, North Carolina 27703

(Address of Principal Executive Offices) (Zip Code)

(919) 859-1302

(Registrant's telephone number, including area code)

 

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common StockBCRXNasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
 
Item 2.02. Results of Operations and Financial Condition.

On August 3, 2023, BioCryst Pharmaceuticals, Inc. (the “Company”) issued a press release announcing recent corporate developments and its financial results for the second quarter ended June 30, 2023, which also referenced a conference call and webcast to discuss these recent corporate developments and financial results.  A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

The information furnished on Exhibit 99.1 is incorporated by reference under this Item 7.01 as if fully set forth herein.

The information in this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description
      
99.1 Press release dated August 3, 2023 entitled "BioCryst Reports Second Quarter 2023 Financial Results and Provides Business Update"
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 BioCryst Pharmaceuticals, Inc.
   
  
Date: August 3, 2023By: /s/ Alane Barnes        
  Alane Barnes
  Chief Legal Officer
  

 

 EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

BioCryst Reports Second Quarter 2023 Financial Results and Provides Business Update

— Q2 2023 ORLADEYO net revenue of $81.0 million (+24 percent y-o-y)—

— On-track to achieve ≥ $320 million in full year 2023 ORLADEYO revenue and $1 billion in peak ORLADEYO revenue—

— Q2 2023 GAAP EPS of ($0.40), non-GAAP EPS of ($0.24), excluding one-time debt extinguishment fee of $29 million—

— BCX10013, once-daily, oral Factor D inhibitor, clinical trial in patients expected to begin enrollment by end of year—

—Company to host R&D day on Friday, November 3rd to introduce additional pipeline assets and programs—

RESEARCH TRIANGLE PARK, N.C., Aug. 03, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.

“Our strong second quarter keeps us firmly on track to achieve no less than $320 million in ORLADEYO revenue this year, as our base of patients grows larger and larger every quarter. While ORLADEYO revenues continue to grow, we are also excited to host an R&D day in November to introduce new molecules and programs from our discovery platform that have the potential to replicate or exceed the success of ORLADEYO,” said Jon Stonehouse, president and chief executive officer of BioCryst.

Program Updates

ORLADEYO® (berotralstat): Oral, Once-daily Treatment for Prevention of Hereditary Angioedema (HAE) Attacks

“The significant step-up in revenue we expected and achieved in the second quarter reflects the continued strong growth in patients taking ORLADEYO, the normal seasonality in revenue that follows first quarter prescription reauthorizations, and our steady improvement in helping patients get to reimbursed therapy. We recently attended the HAEA summit, attended by 1,200 patients and family members. Their strong interest and enthusiasm gave us even more confidence in our expectations for sustained long-term demand for ORLADEYO in the U.S. and globally,” said Charlie Gayer, chief commercial officer of BioCryst.

  • ORLADEYO net revenue in the second quarter of 2023 was $81.0 million (+24.2 percent year-over-year (y-o-y)).

  • Total growth in patients taking ORLADEYO continued on a strong, linear trajectory.

  • The percentage of U.S. ORLADEYO patients receiving paid drug improved in the second quarter as the company made progress converting commercially-insured patients who had been receiving long-term free product, and as patients who received temporary free product during the first quarter prescription re-authorization process returned to reimbursed product in the second quarter.

  • Sales from outside the U.S. contributed 10.1 percent of global ORLADEYO net revenues in the second quarter.

  • The ongoing APeX-P trial in pediatric HAE patients who are 2 to <12 years of age continues to enroll as expected.

BCX10013—Oral Factor D Inhibitor

“Our goal with BCX10013 is to bring a best-in-class molecule to physicians and patients. That means a safe, highly effective, once-daily oral therapy, and we are now focused on preparing for enrollment in our dose-ranging trial in patients,” said Dr. Helen Thackray, chief research and development officer.

  • The company has begun opening clinical trial sites for a dose-ranging trial in patients with paroxysmal nocturnal hemoglobinuria (PNH) and expects to begin patient enrollment (in countries without other approved therapies) by the end of the year. The trial is designed to identify a safe, effective, once-daily dose that BioCryst can advance into a pivotal program in renal complement-mediated diseases.

  • The company also plans to complete an additional cohort of its multiple ascending dose trial (MAD) of BCX10013, at a higher dose (160 mg QD), in healthy volunteers to provide further information to the pharmacokinetic model.

Upcoming R&D Day—November 3, 2023

BioCryst will host a Research and Development (R&D) day at 1:00p ET on Friday, November 3 at its Research Center of Excellence in Birmingham, AL (the event also will be webcast live). At the R&D day, the company plans to introduce additional assets from its pipeline targeting rare diseases.

Second Quarter 2023 Financial Results  

For the three months ended June 30, 2023, total revenues were $82.5 million, compared to $65.5 million in the second quarter of 2022 (+25.9 percent year-over-year (y-o-y)). The increase was primarily due to $81.0 million in ORLADEYO net revenue in the second quarter of 2023, compared to $65.2 million in ORLADEYO net revenue in the second quarter of 2022 (+24.2 percent y-o-y).

R&D expenses for the second quarter of 2023 decreased to $51.2 million from $62.0 million in the second quarter of 2022 (-17.3 percent y-o-y), primarily due to decreased investment in both the BCX9250 and complement programs, partially offset by increased investment in the early-stage pipeline.

Selling, general and administrative expenses for the second quarter of 2023 increased to $51.0 million, compared to $38.0 million in the second quarter of 2022 (+34.1 percent y-o-y). The increase was primarily due to increased investment to support the commercial launch of ORLADEYO and expanded international operations.

Interest expense was $28.9 million in the second quarter of 2023, compared to $24.0 million in the second quarter of 2022 (+20.4 percent y-o-y). The increase is primarily driven by additional interest to service the Pharmakon debt secured in April 2023.

Net loss for the second quarter of 2023 was $75.3 million, or $0.40 per share, compared to a net loss of $58.9 million, or $0.32 per share, for the second quarter of 2022. There was a $29.0 million one-time debt extinguishment fee related to the close-out of the Athyrium debt facility. Excluding this one-time event, non-GAAP net loss for the second quarter of 2023 was $0.24 per share.

Cash, cash equivalents, restricted cash and investments totaled $415.7 million at June 30, 2023, compared to $418.9 million at June 30, 2022. Operating cash use for the second quarter of 2023 was $13.5 million.

Non-GAAP Pro forma Financial Measures

The information furnished in this release includes non-GAAP pro forma financial measures that differ from measures calculated in accordance with generally accepted accounting principles in the United States of America (GAAP), including financial measures labeled as “non-GAAP” or “adjusted.”

We believe providing these non-GAAP measures, which show our pro forma results with these items adjusted, is valuable and useful since they allow the company and investors to better understand the company’s financial performance in the absence of these one-time events and allow investors to more accurately understand our second quarter 2023 results and more easily compare them to future results. These non-GAAP pro forma measures also correspond with the way we expected Wall Street analysts to compare our results. Our non-GAAP pro forma measures should be considered only as supplements to, and not as substitutes for or in isolation from, our other measures of financial information prepared in accordance with GAAP, such as GAAP revenue, operating income, net income, and earnings per share.

Our references to our second quarter 2023 and first six months 2023 “non-GAAP pro forma” financial measures of adjusted net loss and adjusted earnings per share constitute non-GAAP financial measures. They refer to our GAAP results, adjusted to show the results without the one-time loss on the extinguishment of the Athyrium term loans.

Financial Outlook for 2023

The company expects full year 2023 global net ORLADEYO revenue to be no less than $320 million. Operating expenses for full year 2023, not including non-cash stock compensation, are expected to be flat to 2022 at approximately $375 million. While flat year-over-year, we expect reductions in R&D spending in 2023 following the discontinuation of the BCX9930 and BCX9250 programs in 2022 and the delay in the BCX10013 clinical program, offset by increases in SG&A to support the U.S. launch and global expansion of ORLADEYO.

Conference Call and Webcast

BioCryst management will host a conference call and webcast at 8:30 a.m. ET today to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-866-777-2509 for domestic callers and 1-412-317-5413 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO® (berotralstat) is approved in the United States and many global markets. BioCryst has active programs to develop oral medicines for multiple targets across the complement system, including BCX10013, an oral Factor D inhibitor in clinical development. RAPIVAB® (peramivir injection) is approved in the U.S. and multiple global markets, with post-marketing commitments ongoing. For more information, please visit the company’s website at www.biocryst.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: the ongoing COVID-19 pandemic, which could create challenges in all aspects of BioCryst’s business, including without limitation delays, stoppages, difficulties and increased expenses with respect to BioCryst’s and its partners’ development, regulatory processes and supply chains, negatively impact BioCryst’s ability to access the capital or credit markets to finance its operations, or have the effect of heightening many of the risks described below or in the documents BioCryst files periodically with the Securities and Exchange Commission; BioCryst’s ability to successfully implement its commercialization plans for, and to commercialize, ORLADEYO, which could take longer or be more expensive than planned; the results of BioCryst’s partnerships with third parties may not meet BioCryst’s current expectations; risks related to government actions, including that decisions and other actions, including as they relate to pricing, may not be taken when expected or at all, or that the outcomes of such decisions and other actions may not be in line with BioCryst’s current expectations; the commercial viability of ORLADEYO, including its ability to achieve market acceptance; ongoing and future preclinical and clinical development of BCX10013 and other product candidates may take longer than expected and may not have positive results; BioCryst may not be able to enroll the required number of subjects in planned clinical trials of product candidates; BioCryst may not advance human clinical trials with product candidates as expected; the FDA or other applicable regulatory agency may require additional studies beyond the studies planned for products and product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may impose certain restrictions, warnings, or other requirements on products and product candidates, may impose a clinical hold with respect to product candidates, or may withhold, delay or withdraw market approval for products and product candidates; product candidates, if approved, may not achieve market acceptance; BioCryst’s ability to successfully commercialize its products and product candidates, manage its growth and compete effectively; risks related to the international expansion of BioCryst’s business; and actual financial results may not be consistent with expectations, including that revenue, operating expenses and cash usage may not be within management's expected ranges. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which identify important factors that could cause actual results to differ materially from those contained in BioCryst’s projections and forward-looking statements.

BCRXW

Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com



BIOCRYST PHARMACEUTICALS, INC.
CONSOLIDATED FINANCIAL SUMMARY
(in thousands, except per share)
         
Statements of Operations (Unaudited)               
                
  Three Months Ended
  Six Months Ended
  June 30,
  June 30,
  2023 2022  2023 2022
Revenues:               
ORLADEYO$81,009  $65,223  $149,423  $114,927 
Other 1,482   309   1,846   528 
Total revenues 82,491   65,532   151,269   115,455 
                
Expenses:               
Cost of product sales 894   246   1,825   482 
Research and development 51,247   61,990   99,635   127,350 
Selling, general and administrative 50,997   38,017   98,864   72,299 
Royalty 56   1   63   3 
Total operating expenses 103,194   100,254   200,387   200,134 
                
Loss from operations (20,703)  (34,722)  (49,118)  (84,679)
                
Interest and other income 3,750   609   7,128   663 
Interest expense (28,915)  (24,022)  (56,311)  (47,859)
Foreign currency gains (losses), net 301   132   72   (45)
Loss on extinguishment of debt (29,019)  -   (29,019)  - 
Loss before income taxes (74,586)  (58,003)  (127,248)  (131,920)
Income tax expense 740   856   1,411   1,135 
Net loss$(75,326) $(58,859) $(128,659) $(133,055)
                
Basic and diluted net loss per common share$(0.40) $(0.32) $(0.68) $(0.72)
                
Weighted average shares outstanding 189,118   185,605   188,815   185,253 
                
                
Balance Sheet Data (in thousands)               
 June 30, 2023
 December 31, 2022
 (Unaudited)
 (Note 1)
Cash, cash equivalents and investments$414,115
    $442,387
   
Restricted cash 1,574
     1,472
   
Receivables 57,667
     50,599
   
Total assets 529,885
     550,000
   
Secured term loan 293,176
     231,624
   
Royalty financing obligation 526,121
     501,655
   
Accumulated deficit (1,583,279)    (1,454,620)  
Stockholders’ deficit (388,713)    (294,597)  
Shares of common stock outstanding 189,491
     187,906
   
                
Note 1: Derived from audited financial statements.               
                
                
Reconciliation of Adjusted Net Income and Adjusted Diluted Earnings Per Share (in thousands)
                
  Three Months Ended  Six Months Ended
  June 30,  June 30,
  2023  2022  2023  2022
GAAP net loss$(75,326) $(58,859) $(128,659) $(133,055)
Less : One-time loss on extinguishment of Athyrium term loans (29,019)  -   (29,019)  - 
Adjusted net loss$(46,307) $(58,859) $(99,640) $(133,055)
                
GAAP basic and diluted net loss per common share$(0.40) $(0.32) $(0.68) $(0.72)
                
Adjusted basic and diluted net loss per common share$(0.24) $(0.32) $(0.53) $(0.72)
                

 

 

 EX-101.SCH 3 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20190101_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20190101_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Aug. 03, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 03, 2023
Entity File Number 000-23186
Entity Registrant Name BioCryst Pharmaceuticals, Inc.
Entity Central Index Key 0000882796
Entity Tax Identification Number 62-1413174
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 4505 Emperor Blvd., Suite 200
Entity Address, City or Town Durham
Entity Address, State or Province NC
Entity Address, Postal Zip Code 27703
City Area Code 919
Local Phone Number 859-1302
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol BCRX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 f8k_080323_htm.xml IDEA: XBRL DOCUMENT 0000882796 2023-08-03 2023-08-03 iso4217:USD shares iso4217:USD shares 0000882796 false 8-K 2023-08-03 BioCryst Pharmaceuticals, Inc. DE 000-23186 62-1413174 4505 Emperor Blvd., Suite 200 Durham NC 27703 919 859-1302 false false false false Common Stock BCRX NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_080323.htm exh_991.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f8k_080323.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "contextCount": 1, "dts": { "definitionLink": { "local": [ "gnw-20190101_def.xml" ] }, "inline": { "local": [ "f8k_080323.htm" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_080323.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://globenewswire.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_080323.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001171843-23-004942-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-23-004942-xbrl.zip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